AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26297371 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS plus exercise
Number of subjects: 20
Study 26297371 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS plus exercise
Number of subjects: 20
Study 23873171 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16/18 vaccine
Number of subjects: 7466
Study 23873171 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis A vaccine (control)
Number of subjects: 7466
Study 21932579 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized Mixed Diet (OMD)
Number of subjects: 17
Study 21932579 — intervention group
Group type: COMPARATOR
Intervention: Low-Glycemic Index Diet (low-GI)
Number of subjects: 17
Study 21932579 — intervention group
Group type: COMPARATOR
Intervention: Both OMD and low-GI
Number of subjects: 17
Study 18986845 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine
Number of subjects: 0
Study 18986845 — intervention group
Group type: COMPARATOR
Intervention: Thermal contact (heater probe, bipolar electrocoagulation)
Number of subjects: 0
Study 18986845 — intervention group
Group type: COMPARATOR
Intervention: Sclerosant therapy
Number of subjects: 0
Study 18986845 — intervention group
Group type: COMPARATOR
Intervention: Clips
Number of subjects: 0
Study 18986845 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy
Number of subjects: 0
Study 18986845 — intervention group
Group type: COMPARATOR
Intervention: Bolus followed by continuous-infusion proton pump inhibitor
Number of subjects: 0
Study 17976093 — intervention group
Group type: EXPERIMENTAL
Intervention: Multielectrode basket catheter (MBC) for pulmonary vein isolation (PVI)
Number of subjects: 200
Study 17976093 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal ablation guided by MBC
Number of subjects: 200
Study 15562880 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual swallow immunotherapy with ragweed allergen extract
Number of subjects: 83
Study 15562880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 11566454 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone treatment (6 mg/day)
Number of subjects: 108
Study 11566454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 9623371 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoplethysmography (PPG)
Number of subjects: 32
Study 9623371 — intervention group
Group type: COMPARATOR
Intervention: Hand-held Doppler
Number of subjects: 32
Study 7821475 — intervention group
Group type: EXPERIMENTAL
Intervention: Amethocaine cream
Number of subjects: 169
Study 7821475 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 169
Study 7821475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 7821475 — intervention group
Group type: EXPERIMENTAL
Intervention: Amethocaine vs EMLA
Number of subjects: 169
Study 3076791 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous terbutaline
Number of subjects: 22
Study 3076791 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous terbutaline (continuous infusion and 6‐hourly divided dose regimens)
Number of subjects: 22
Study 29071556 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol combined with hydration (probucol 500 mg twice daily and hydration)
Number of subjects: 641
Study 29071556 — intervention group
Group type: COMPARATOR
Intervention: Hydration only (control group)
Number of subjects: 641
Study 29071556 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol combined with hydration
Number of subjects: 641
Study 29071556 — intervention group
Group type: COMPARATOR
Intervention: Probucol combined with hydration and hydration only
Number of subjects: 641
Study 27784336 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 28
Study 27784336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 26084979 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured mobile phone‐based health coaching program supported by a remote monitoring system
Number of subjects: 517
Study 26084979 — intervention group
Group type: COMPARATOR
Intervention: Current practice (control)
Number of subjects: 517
Study 22686135 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification intervention (diet and exercise)
Number of subjects: 61
Study 19780631 — intervention group
Group type: EXPERIMENTAL
Intervention: SCTG with Er:YAG laser application
Number of subjects: 12
Study 19780631 — intervention group
Group type: COMPARATOR
Intervention: SCTG without Er:YAG laser application (control group)
Number of subjects: 12
Study 18685499 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium adolescentis DSM 18350, B. adolescentis DSM 18352, Bifidobacterium pseudocatenulatum DSM 18353 (5 x 10^9 colony forming units/d)
Number of subjects: 23
Study 18685499 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium adolescentis DSM 18352
Number of subjects: 23
Study 14767696 — intervention group
Group type: EXPERIMENTAL
Intervention: BDX + GTR
Number of subjects: 8
Study 14767696 — intervention group
Group type: EXPERIMENTAL
Intervention: BDX Coll + GTR
Number of subjects: 8
Study 11594260 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study 11594260 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 9572083 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (amino acid beverage containing no tryptophan)
Number of subjects: 11
Study 9572083 — intervention group
Group type: COMPARATOR
Intervention: Sham depletion (amino acid beverage containing tryptophan)
Number of subjects: 11
Study 7786690 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium
Number of subjects: 95
Study 7786690 — intervention group
Group type: COMPARATOR
Intervention: Intravenous propranolol
Number of subjects: 95
Study 3208796 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine calcitonin in physiological saline
Number of subjects: 9
Study 3208796 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine calcitonin in hydrolysed gelatin
Number of subjects: 9
Study 28796014 — intervention group
Group type: COMPARATOR
Intervention: Primary Wound Closure (PC)
Number of subjects: 604
Study 28796014 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed Primary Wound Closure (DPC)
Number of subjects: 604
Study 27762569 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational check-in (MCI); 3 MET-based check-in sessions at 4, 7, and 10 months after baseline.
Number of subjects: 252
Study 27762569 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only check-in (ACI); 3 assessment-only check-in sessions at 4, 7, and 10 months after baseline.
Number of subjects: 252
Study 24811580 — intervention group
Group type: EXPERIMENTAL
Intervention: ALP Animated Graphics
Number of subjects: 0
Study 24811580 — intervention group
Group type: COMPARATOR
Intervention: Picture Communication Symbols (PCS)
Number of subjects: 0
Study 24811580 — intervention group
Group type: EXPERIMENTAL
Intervention: Animated symbols
Number of subjects: 0
Study 24811580 — intervention group
Group type: EXPERIMENTAL
Intervention: ALP symbols for prepositions
Number of subjects: 0
Study 24811580 — intervention group
Group type: EXPERIMENTAL
Intervention: Older children
Number of subjects: 0
Study 21981307 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant Behavioral Assessment (IBA)
Number of subjects: 169
Study 21055705 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Number of subjects: 21
Study 21055705 — intervention group
Group type: COMPARATOR
Intervention: Placebo taping
Number of subjects: 21
Study 21055705 — intervention group
Group type: COMPARATOR
Intervention: Without taping
Number of subjects: 21
Study 17609022 — intervention group
Group type: EXPERIMENTAL
Intervention: Podophyllin 25% and cryotherapy concurrently
Number of subjects: 409
Study 17609022 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichloracetic acid or podophyllin 25% (single therapy)
Number of subjects: 409
Study 15625221 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video about the consent process in treatment research
Number of subjects: 0
Study 15625221 — intervention group
Group type: COMPARATOR
Intervention: Control videotape presenting general information about bioethical issues in human research
Number of subjects: 0
Study 11682424 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% plus epinephrine 1:200,000
Number of subjects: 41
Study 11682424 — intervention group
Group type: COMPARATOR
Intervention: Plain ropivacaine 0.5%
Number of subjects: 41
Study 11682424 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% plus epinephrine 1:200,000
Number of subjects: 41
Study 11682424 — intervention group
Group type: COMPARATOR
Intervention: Plain ropivacaine 0.2%
Number of subjects: 41
Study 9462166 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (Vitamin E) 600 mg twice a day for 12 weeks
Number of subjects: 42
Study 9462166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 7949636 — intervention group
Group type: COMPARATOR
Intervention: Single oral dose of cisapride (5 mg)
Number of subjects: 8
Study 7949636 — intervention group
Group type: COMPARATOR
Intervention: Oral cisapride (15 mg TID) for 14 days
Number of subjects: 8
Study 7949636 — intervention group
Group type: COMPARATOR
Intervention: Single oral dose of cisapride (5 mg) after 14 days of treatment
Number of subjects: 8
Study 2897556 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Number of subjects: 30
Study 2897556 — intervention group
Group type: COMPARATOR
Intervention: No hypnotherapy (Control)
Number of subjects: 30
Study 31690049 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg/bm)
Number of subjects: 13
Study 31690049 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 13
Study 28121915 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise in hypoxia (4200 m)
Number of subjects: 9
Study 28121915 — intervention group
Group type: COMPARATOR
Intervention: Moderate exercise in normoxia
Number of subjects: 9
Study 25727442 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline tablets
Number of subjects: 140
Study 25727442 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patches
Number of subjects: 140
Study 23843980 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin regimen (4 months with isoniazid, rifampicin, and pyrazinamide for first 2 months)
Number of subjects: 416
Study 23843980 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin regimen (4 months with isoniazid, rifampicin, and pyrazinamide for first 2 months)
Number of subjects: 416
Study 23843980 — intervention group
Group type: COMPARATOR
Intervention: Control regimen (6 months with isoniazid, rifampicin, ethambutol, and pyrazinamide for first 2 months)
Number of subjects: 416
Study 23843980 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin regimen (for drug-resistant patients)
Number of subjects: 416
Study 23843980 — intervention group
Group type: COMPARATOR
Intervention: Control regimen (for drug-resistant patients)
Number of subjects: 416
Study 20934277 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (55 Gy in 20 fractions within 4 weeks)
Number of subjects: 217
Study 20934277 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (64 Gy in 32 fractions within 6.5 weeks)
Number of subjects: 217
Study 20934277 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 217
Study 20934277 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 217
Study 19346845 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerine (NTG)
Number of subjects: 30
Study 19346845 — intervention group
Group type: COMPARATOR
Intervention: Control group (without NTG)
Number of subjects: 30
Study 16720918 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg, three times daily) and alpha-tocopherol (300 mg, twice daily) during radiotherapy, followed by 400 mg of PTX and 300 mg of alpha-tocopherol daily for 3 months after radiotherapy
Number of subjects: 66
Study 16720918 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy only (control group)
Number of subjects: 66
Study 15292629 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational family intervention (12 sessions, 90 minutes each)
Number of subjects: 45
Study 15292629 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 45
Study 11743460 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepragel sinus (hylan B gel)
Number of subjects: 10
Study 11743460 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 10
Study 9401808 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime
Number of subjects: 122
Study 9401808 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole‐gentamicin
Number of subjects: 122
Study 9401808 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 122
Study 8353699 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (community-based psychiatric services)
Number of subjects: 172
Study 8353699 — intervention group
Group type: COMPARATOR
Intervention: Control group (hospital-based care)
Number of subjects: 172
Study 30160584 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi classes for 3 or 4 weeks
Number of subjects: 10
Study 28741390 — intervention group
Group type: EXPERIMENTAL
Intervention: Low maternal haemoglobin level (<130 g/L) in the first trimester
Number of subjects: 10430
Study 28741390 — intervention group
Group type: EXPERIMENTAL
Intervention: High maternal haemoglobin level (≥130 g/L) in the second trimester
Number of subjects: 10430
Study 28741390 — intervention group
Group type: COMPARATOR
Intervention: Normal maternal haemoglobin levels in both trimesters
Number of subjects: 10430
Study 26429408 — intervention group
Group type: EXPERIMENTAL
Intervention: Locked Less Invasive Stabilization System (LISS; Synthes, Paoli, PA)
Number of subjects: 52
Study 26429408 — intervention group
Group type: COMPARATOR
Intervention: Dynamic Condylar Screw (DCS)
Number of subjects: 52
Study 25179587 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1200 mg, twice daily, added to contingency management
Number of subjects: 300
Study 25179587 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO), matched to NAC, added to contingency management
Number of subjects: 300
Study 21939972 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous lateral rotational therapy (CLRT) for 5 days
Number of subjects: 27
Study 21939972 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional positioning)
Number of subjects: 27
Study 20713903 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial artery (RA) grafts
Number of subjects: 27
Study 20713903 — intervention group
Group type: COMPARATOR
Intervention: Saphenous vein (SV) grafts
Number of subjects: 27
Study 18312071 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidic fibroblast growth factor (FGF) applied during nerve repair surgery
Number of subjects: 9
Study 16263986 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-allergen maternal diet (excluded cow's milk, eggs, peanuts, tree nuts, wheat, soy, and fish)
Number of subjects: 90
Study 16263986 — intervention group
Group type: COMPARATOR
Intervention: Control group (continued to consume allergenic foods)
Number of subjects: 90
Study 16263986 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-allergen maternal diet
Number of subjects: 90
Study 12927761 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% tropicamide
Number of subjects: 17
Study 12927761 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005% tropicamide
Number of subjects: 17
Study 10552287 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8813487 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 0
Study 1642945 — intervention group
Group type: EXPERIMENTAL
Intervention: esmolol hydrochloride
Number of subjects: 30
Study 1642945 — intervention group
Group type: COMPARATOR
Intervention: normal saline
Number of subjects: 30
Study 6666215 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous isosorbide dinitrate (50‐200 micrograms/kg/h)
Number of subjects: 28
Study 6666215 — intervention group
Group type: COMPARATOR
Intervention: Intravenous frusemide (1 mg/kg)
Number of subjects: 28
Study 31615840 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg)
Number of subjects: 78
Study 31615840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 30223252 — intervention group
Group type: EXPERIMENTAL
Intervention: Aptima HPV (AHPV)
Number of subjects: 3475
Study 30223252 — intervention group
Group type: COMPARATOR
Intervention: Hybrid Capture 2 (HC2)
Number of subjects: 3475
Study 30223252 — intervention group
Group type: EXPERIMENTAL
Intervention: AHPV
Number of subjects: 3475
Study 30223252 — intervention group
Group type: COMPARATOR
Intervention: HC2
Number of subjects: 3475
Study 30223252 — intervention group
Group type: EXPERIMENTAL
Intervention: AHPV- women
Number of subjects: 3475
Study 30223252 — intervention group
Group type: COMPARATOR
Intervention: HC2- women
Number of subjects: 3475
Study 26985851 — intervention group
Group type: EXPERIMENTAL
Intervention: IHW‐S (Indigenous health worker supported)
Number of subjects: 193
Study 26985851 — intervention group
Group type: COMPARATOR
Intervention: UC (Usual care)
Number of subjects: 193
Study 24139147 — intervention group
Group type: EXPERIMENTAL
Intervention: Left cathodal/right anodal transcranial direct current stimulation (tDCS) over the dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 0
Study 24139147 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation over the dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 0
Study 22554721 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg the night before surgery)
Number of subjects: 390
Study 19781622 — intervention group
Group type: EXPERIMENTAL
Intervention: Maca extract (ME)
Number of subjects: 8
Study 19781622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 17633371 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenqi Fuzheng Injection (SQFZI), 250 mL via intravenous dripping starting from 5 days before operation and after ending CPB once a day.
Number of subjects: 20
Study 17633371 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 20
Study 14715085 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly diagnosed cancer
Number of subjects: 504
Study 11641659 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy
Number of subjects: 10
Study 11641659 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 10
Study 11641659 — intervention group
Group type: COMPARATOR
Intervention: Pregnancy (any trimester)
Number of subjects: 10
Study 9870832 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 400 mg orally daily
Number of subjects: 106
Study 9870832 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B 0.5 mg/kg/day
Number of subjects: 106
Study 8205374 — intervention group
Group type: EXPERIMENTAL
Intervention: Flogan (potassium diclofenac suspension)
Number of subjects: 18
Study 8205374 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataflam (potassium diclofenac suspension)
Number of subjects: 18
Study 2488496 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D 4,000 IU per day
Number of subjects: 0
Study 2488496 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injections of ergocalciferol 600,000 IU every six months
Number of subjects: 0
Study 2488496 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake of at least 1 g per day
Number of subjects: 0
Study 2488496 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral ergocalciferol
Number of subjects: 0
Study 1096276 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenazone 600 mg daily
Number of subjects: 20
Study 1096276 — intervention group
Group type: COMPARATOR
Intervention: Phenylbutazone 300 mg daily
Number of subjects: 20
Study 31286828 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (active rTMS + fluoxetine)
Number of subjects: 27
Study 31286828 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham rTMS + placebo fluoxetine)
Number of subjects: 27
Study 31286828 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (sham rTMS + fluoxetine)
Number of subjects: 27
Study 28455259 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulated Normative group
Number of subjects: 251
Study 28455259 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized Normative group
Number of subjects: 251
Study 28455259 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 251
Study 25653511 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg monotherapy
Number of subjects: 335
Study 25653511 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg + antihypertensive combination therapy
Number of subjects: 335
Study 23169790 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined digital mammography and breast tomosynthesis
Number of subjects: 1192
Study 23169790 — intervention group
Group type: COMPARATOR
Intervention: Digital mammography alone
Number of subjects: 1192
Study 21046285 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 114 (15 μg)
Number of subjects: 48
Study 21046285 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 114 (50 μg)
Number of subjects: 48
Study 21046285 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 114 (200 μg)
Number of subjects: 48
Study 21046285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 19298680 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 30
Study 19298680 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 30
Study 16505651 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin-minocycline (RM) coated catheters
Number of subjects: 646
Study 16505651 — intervention group
Group type: COMPARATOR
Intervention: Silver-platinum-carbon (SPC) impregnated catheters
Number of subjects: 646
Study 14567807 — intervention group
Group type: EXPERIMENTAL
Intervention: SprayGel adhesion barrier
Number of subjects: 14
Study 10928668 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% brimonidine
Number of subjects: 81